Results 131 to 140 of about 1,156,270 (203)

Clinical and Genetic Analysis of Pediatric Neurodevelopmental Disorders With Complex Chromosomal Rearrangements in Two Cases

Molecular Genetics &Genomic Medicine, Volume 14, Issue 9, September 2026.
This study investigates the impact of complex chromosomal rearrangement (CCR) breakpoints on pediatric developmental delay and epilepsy. By integrating karyotype analysis with WES and/or WGS, we identified an inversion on chromosome 3 likely affecting ROBO1/DNAJC13/ACAD11 in one patient and a complex chromosome 1 rearrangement with a novel KCNA2 ...
Jiaci Li, Wenxuan Fan, Nan Liu, Shuyue Zhang, Ping Wang, Chunyu Gu, Jianbo Shu   +6 more
wiley   +1 more source

A rare pericallosal lipoma presenting with Lennox-Gastaut syndrome and a remarkable response to valproic acid. [PDF]

Epileptic Disord
Rapal RMLL, Chin HL, Nordli D.
europepmc   +1 more source

Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990–2021)

Neuroprotection, Volume 4, Issue 3, Page 199-212, September 2026.
Epilepsy: Global Trends and the Chinese Experience (1990–2021). The infographic depicts (left) the global distribution of age‐standardized epilepsy DALY rates; (center) the triple inequality gap within China, including regional mortality disparities (9‐fold difference between western and eastern provinces), urban‐rural treatment gaps (60%–90%), and ...
Ting Chen, Mengqiao He, Sijia Basang, Hongyu Ren, Yutong Fu, Yu Li, Xin Shi, Lei Chen   +7 more
wiley   +1 more source

Real-world outcomes of responsive neurostimulation in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. [PDF]

Epilepsia Open
Swartwood SM, Bollo RJ, Chu CJ, Geffrey AL, Richardson RM, Nariai H, Fallah A, Ahn S, Ghatan S, Chenevert L, La Vega-Talbott M, Espinoza AC.   +11 more
europepmc   +1 more source

Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 3, September 2026.
Abstract Cannabinoid products are increasingly used worldwide despite limited psychiatric evidence. This narrative review synthesizes preclinical and clinical evidence on cannabidiol (CBD), cannabinol (CBN), and tetrahydrocannabinol (THC) to clarify their distinct psychiatric profiles and discuss how current evidence may inform ongoing clinical and ...
Yasuhiro Kishi, Ichiro Takumi, Kakusho Chigusa Nakajima‐Ohyama   +2 more
wiley   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome. [PDF]

Epilepsia
Guerrini R, Marsh ED, Liao WP, Imai K, Kravljanac R, Altmann A, Hahn CD, Auvin S, Schiemann J, Khan Y, Mitra P, Sheikh SI, von Rosenstiel P, Asgharnejad M, Dlugos D, Murthy V.   +15 more
europepmc   +1 more source

Safety of synthetic cannabidiol as a novel food pursuant to regulation (EU) 2015/2283

EFSA Journal, Volume 24, Issue 9, September 2026.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on cannabidiol (CBD) obtained by chemical synthesis as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Francesco Cubadda, Harry J. McArdle, Viviana Trezza, Océane Albert, Elisa Beneventi, Marcello Laganaro, Irene Nuin Garciarena, Annamaria Rossi, Sebastián Berrío Cruz, Francesca Seminati, Maura Magani, Karen Ildico Hirsch‐Ernst   +26 more
wiley   +1 more source

Compounded Complexity: The Impact of Social Determinants of Health on a Child With Cerebral Palsy and Lennox-Gastaut Syndrome. [PDF]

Cureus
Caldes N, Perez NM, Quintero J, Semidey K.   +3 more
europepmc   +1 more source

Safety of cannabidiol isolated from Cannabis sativa L. as a novel food pursuant to Regulation (EU) 2015/2283

EFSA Journal, Volume 24, Issue 9, September 2026.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on cannabidiol (CBD) isolated from Cannabis sativa L. as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF consists of ≥ 98% w/w CBD.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Francesco Cubadda, Harry J. McArdle, Viviana Trezza, Océane Albert, Elisa Beneventi, Marcello Laganaro, Irene Nuin Garciarena, Annamaria Rossi, Sebastián Berrío Cruz, Francesca Seminati, Maura Magani, Karen Ildico Hirsch‐Ernst   +26 more
wiley   +1 more source